Consolidated Statements Of Cash Flows - USD ($)	12 Months Ended
	Jan. 28, 2024	Jan. 29, 2023	Jan. 30, 2022
Cash flows from operating activities:
Net income	$ (1,092,029,000)	$ 61,372,000	$ 125,645,000
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation and amortization	77,968,000	32,151,000	30,892,000
Amortization of right-of-use assets	6,484,000	4,742,000	4,410,000
Right-of-use asset impairment	3,884,000	0	0
Investment impairments and credit loss reserves, net	3,929,000	1,156,000	1,337,000
Impairment of goodwill	755,621,000	0	0
Intangible impairment	131,385,000	0	0
Accretion of deferred financing costs and debt discount	7,320,000	1,421,000	481,000
Write-off of deferred financing cost and debt discount	4,446,000	0	0
Deferred income taxes	40,636,000	(15,256,000)	(3,782,000)
Share-based compensation	40,170,000	39,248,000	51,189,000
Loss (gain) on disposition of business operations and assets	8,000	(18,260,000)	(54,000)
Changes in the fair value of contingent earn-out obligations	0	0	(13,000)
Equity in net (gains) losses of equity method investments	(45,000)	(249,000)	(2,115,000)
Corporate owned life insurance, net	4,746,000	810,000	4,766,000
Amortization of inventory step-up	3,314,000	0	0
Changes in assets and liabilities:
Accounts receivable, net	27,443,000	2,445,000	(1,074,000)
Inventories	57,308,000	(3,752,000)	(26,509,000)
Other assets	1,817,000	6,302,000	11,176,000
Accounts payable	(44,346,000)	(3,697,000)	(2,145,000)
Accrued liabilities	(118,517,000)	18,921,000	17,829,000
Other liabilities	(5,462,000)	(643,000)	(8,910,000)
Net cash (used in) provided by operating activities	(93,920,000)	126,711,000	203,123,000
Cash flows from investing activities:
Proceeds from sales of property, plant and equipment	410,000	38,000	110,000
Purchase of property, plant and equipment	(29,185,000)	(28,323,000)	(26,181,000)
Proceeds from sale of investments	0	2,275,000	0
Purchase of investments	(930,000)	(6,748,000)	(8,245,000)
Purchase of intangibles	(1,915,000)	0	0
Proceeds from sale of business, net of cash disposed	0	26,193,000	0
Acquisition, net of cash acquired	0	(1,240,757,000)	0
Proceeds from corporate-owned life insurance	8,923,000	5,065,000	0
Premiums paid for corporate-owned life insurance	0	(5,065,000)	(6,000,000)
Net cash used in investing activities	(22,697,000)	(1,247,322,000)	(40,316,000)
Cash flows from financing activities:
Proceeds from revolving line of credit	70,000,000	10,000,000	20,000,000
Payments of revolving line of credit	(5,000,000)	(33,000,000)	(28,000,000)
Proceeds from term loans	0	895,000,000	0
Payments of term loans	(272,375,000)	0	0
Proceeds from convertible senior notes	250,000,000	319,500,000	0
Proceeds from sale of warrants	0	42,909,000	0
Purchase of convertible note hedge	0	(72,559,000)	0
Deferred financing costs	(25,361,000)	(21,760,000)	0
Payments of earn-out	0	0	(215,000)
Payments for employee share-based compensation payroll taxes	(6,714,000)	(14,190,000)	(19,413,000)
Proceeds from exercise of stock options	0	620,000	5,277,000
Repurchase of common stock	0	(50,000,000)	(129,746,000)
Net cash provided by (used in) financing activities	10,550,000	1,076,520,000	(152,097,000)
Net (decrease) increase in cash and cash equivalents	(106,925,000)	(44,091,000)	10,710,000
Cash and cash equivalents at beginning of period	235,510,000	279,601,000	268,891,000
Cash and cash equivalents at end of period	128,585,000	235,510,000	279,601,000
Supplemental disclosure of cash flow information
Interest paid	83,583,000	11,745,000	4,295,000
Income taxes paid	19,758,000	10,364,000	3,333,000
Non-cash items
Capital expenditures in accounts payable	860,000	9,390,000	5,513,000
Accrued deferred financing costs	828,000	2,767,000	0
Conversion of note into equity	1,271,000	0	626,000
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	$ (858,000)	$ 0	$ 0